Clinical Trials
8 trialsNCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT06099990 2023-10-25
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Not yet recruiting
NCT01637402 2020-08-17
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT01594918 2017-07-21
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT00399087 2014-02-13
Phase I Trial of Docetaxel With Perifosine
AEterna Zentaris
Phase 1 Completed